Our data suggest a mechanism of MIR139 silencing in MLL-AF9 AML in which PRC2 activity and recruitment of POLR2M at the E1, E2 inhibit MIR139 expression to promote oncogenesis (Fig. 7). Here, KMT2A is linked to acute myeloid leukemia.